Overview

* Edwards Lifesciences ( EW ) Q3 sales grow 14.7% to $1.55 bln, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, driven by comprehensive portfolio growth

* Company raises full-year sales and adj EPS guidance, reflecting better-than-expected performance

Outlook

* Edwards raises 2025 sales growth guidance to high end of 9-10%

* Company increases TAVR sales guidance to 7-8% from 6-7%

* Edwards lifts 2025 adjusted EPS guidance to $2.56-$2.62

Result Drivers

* TAVR SALES - Growth driven by new clinical evidence, updated guidelines, and expanding indications, with stable pricing and competitive position

* TMTT GROWTH - Driven by strong adoption of PASCAL and EVOQUE systems, with support from new ESC/EACTS guidelines

* EUROPEAN MARKET - Exit of a competitor in Europe contributed modestly to sales growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $1.55 $1.49

bln bln (29

Analysts

)

Q3 Beat $0.67 $0.59

Adjusted (26

EPS Analysts

)

Q3 EPS $0.50

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 14 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Edwards Lifesciences Corp ( EW ) is $88.00, about 6% above its October 29 closing price of $82.69

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)